Attorney Docket: DFS-044.01

REMARKS

Claims 1-50 are currently pending in the application.

In a Response to the Restriction Requirement in the above-identified application, filed August 7, 2006, Applicants elected, without traverse, **Group I**, for prosecution on the merits. Group I, claims 1-18, is drawn to an isolated MHC class II protein occupied by a space holder molecule, classified in Class 530, subclass 350.

Applicants also provisionally elected SEQ ID NO: 36 for search purposes only.

Applicants now elect an effector component as required by the Restriction Requirement. Applicants provisionally elect the effector component, biotin, for search purposes only.

Applicants expressly reserve the right to prosecute non-elected claims and species in other patent applications claiming the benefit of the filing date of this application. Furthermore, Applicants understand that upon allowance of a generic claims, they will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of any allowed generic claims.

Early and favorable consideration of the application is respectfully solicited. The Examiner may address any questions raised by this submission to the undersigned at (617) 832-1738. If any fees are due, the Commissioner is hereby authorized to credit any overpayment or charge any deficiencies to Deposit Account No. **Deposit Account No. 06-1448, DFS-044.01**.

Respectfully submitted, FOLEY HOAG

<u>Dated: November 21, 2006</u> <u>Customer Number 25181</u>

Patent Group Foley Hoag LLP 155 Seaport Blvd. Boston, MA 02210-2600

Tel: (617) 832-1738 FAX: (617) 832-7000 Charlene A. Stera-Dombal, Ph.D.

Reg. No. 57,961 Agent for Applicants